688513.SHG Chengdu Easton Biopharmaceuticals Co Ltd
- Market cap
- CNY 7.48B
- P/E
- 26.8x
- P/B
- 2.40x
- ROE
- 9.3%
- Dividend yield
- 1.03%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688513.SHG undervalued?
Graham number688513.SHG trades 69.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chengdu Easton Biopharmaceuticals Co Ltd fundamental analysis
No fundamental analysis for Chengdu Easton Biopharmaceuticals Co Ltd yet.
Chengdu Easton Biopharmaceuticals Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients; finished dosage forms, including capsules, tablets, and injections; pharmaceutical intermediates; biological drugs; and generic drugs. Its products are used in oncology, cardiovascular, neurology and psychiatry, anes…
Full company profileChengdu Easton Biopharmaceuticals Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chengdu Easton Biopharmaceuticals Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 339M | 476M | 769M | 947M | 922M | 1.02B | 1.17B | 1.12B | 1.35B | 1.33B | 1.32B |
| Gross Profit | 269M | 403M | 680M | 851M | 814M | 877M | 971M | 890M | 1.00B | 1.33B | 1.01B |
| Operating Income | 39.4M | 74.3M | 149M | 115M | 199M | 244M | 261M | 242M | 252M | 313M | 249M |
| EBITDA | 61.6M | 97.9M | 173M | 144M | 233M | 280M | 323M | 319M | 338M | 381M | 278M |
| Net Income | 57.3M | 64.4M | 135M | 109M | 178M | 232M | 247M | 227M | 238M | 283M | 278M |
| EPS | 0.66 | 0.49 | 1.02 | 0.82 | 1.21 | 1.32 | 1.39 | 1.28 | 1.36 | 1.63 | 1.58 |
| Balance Sheet | |||||||||||
| Total Assets | 520M | 592M | 790M | 987M | 2.53B | 2.78B | 3.02B | 3.35B | 3.40B | 3.80B | 3.94B |
| Total Liabilities | 130M | 147M | 208M | 290M | 436M | 484M | 573M | 743M | 702M | -2.87B | 874M |
| Shareholders' Equity | 390M | 445M | 582M | 697M | 2.10B | 2.29B | 2.44B | 2.60B | 2.70B | 2.87B | 2.99B |
| Cash & Short-term Investments | 227M | 273M | 365M | 404M | 1.63B | 1.50B | 1.35B | 1.52B | 1.42B | 1.57B | 417M |
| Total Debt | - | - | - | 4.69M | 40.0M | 20.0M | 105M | 221M | 110M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 106M | 85.7M | 167M | 142M | 157M | 148M | 152M | 275M | 263M | 265M | - |
| Capital Expenditure | 17.8M | 23.0M | 76.6M | 95.4M | 199M | 256M | 339M | 175M | 117M | 86.3M | 81.6M |
| Free Cash Flow | 88.2M | 62.7M | 90.2M | 46.4M | -42.3M | -109M | -187M | 100.0M | 146M | 179M | 204M |
| Ratios | |||||||||||
| ROE | 14.7% | 14.5% | 23.2% | 15.6% | 8.5% | 10.1% | 10.1% | 8.7% | 8.8% | 9.9% | 9.3% |
| ROA | 11.0% | 10.9% | 17.1% | 11.0% | 7.0% | 8.4% | 8.2% | 6.8% | 7.0% | 7.5% | 7.1% |
| Net Profit Margin | 16.9% | 13.5% | 17.6% | 11.5% | 19.3% | 22.7% | 21.1% | 20.3% | 17.7% | 21.3% | 21.1% |
| Debt to Equity | - | - | - | 0.01x | 0.02x | 0.01x | 0.04x | 0.08x | 0.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chengdu Easton Biopharmaceuticals Co Ltd dividends
- Dividend yield
- 1.03%
- Forward dividend
- 0.49 CNY
- Payout ratio
- 27.1%
- Ex-dividend date
- Jun 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 76.8M | 0.44 | 27.1% |
| 2024 | CNY 74.1M | 0.42 | 31.1% |
| 2023 | CNY 71.1M | 0.40 | 31.4% |
| 2022 | CNY 93.7M | 0.53 | 38.0% |
| 2021 | CNY 36.0M | 0.20 | 15.5% |
| 2020 | CNY 696K | 0.00 | 0.4% |
| 2019 | CNY 22.5M | 0.17 | 20.7% |
| 2018 | - | - | - |
| 2017 | 22.5M | 0.17 | 35.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.47:1 on Jul 1, 2024.
Who owns Chengdu Easton Biopharmaceuticals Co Ltd
- Insiders 50.29%
- Institutions 10.69%
- Public & others 39.03%
- Shares outstanding 177M
- Free float 81.1M
Chengdu Easton Biopharmaceuticals Co Ltd company profile
- Company name
- Chengdu Easton Biopharmaceuticals Co Ltd
- Ticker
- 688513.SHG
- ISIN
- CNE100004397
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,480
- Fiscal year end
- December
- Address
- No. 8, Ankang Road, Chengdu, China, 610200
- Phone
- 86 28 8782 7191
- Website
- eastonpharma.cn
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients; finished dosage forms, including capsules, tablets, and injections; pharmaceutical intermediates; biological drugs; and generic drugs. Its products are used in oncology, cardiovascular, neurology and psychiatry, anesthetic and analgesics, urinary, anti-inflammatory, anti-diabetes, anthelmintic, and antiemetic therapeutic categories. The company was founded in 2009 and is headquartered in Chengdu, China.
Chengdu Easton Biopharmaceuticals Co Ltd management
6- Mr. Mingxu YuanGM & Director · born 1972
- Ms. Xiao Qin BoCFO & Director · born 1982
- Mr. Daming ZhangDeputy GM & Director · born 1973
- Ms. Shuyun LiBoard Secretary · born 1985
- Mr. Zheng Pin GuanDeputy GM & Core Technician · born 1974
- Mr. Xingyao SongDeputy General Manager · born 1977